Jyrki Vähätalo
Research Subjects
Research Interests
Jyrki Vähätalo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Heikki Minn
Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.
3 shared publications - Iiro Auterinen
VTT Technical Research Centre of Finland, Espoo, Finland
3 shared publications Juha Jääskeläinen
Kuopio University Central Hospital
3 shared publicationsMartti Kulvik
Helsinki University Central Hospital
3 shared publicationsAnders Paetau
Department of Pathology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029 HUCH, Finland
2 shared publicationsEija Järviluoma
University of Helsinki
2 shared publications
Latest Publications
- 29 July 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (1) , 87-94
Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET
Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[18F]fluoro-L-phenylalanine ([18F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible. We studied dynamic uptake of [18F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [18F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [18F]FBPA tissue activity gradients. Model fits with three parameters K 1 (transport), k 2 (reverse transport) and k 3 (intracellular metabolism) were found to best illustrate [18F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [18F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [18F]FBPA influx constant (K i -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1–1.4. [18F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [18F]FBPA, some of these benign neoplasms may be amenable to BNCT.
- 29 July 2006
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (1) , 87-94
Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET
Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[18F]fluoro-L-phenylalanine ([18F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible. We studied dynamic uptake of [18F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [18F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [18F]FBPA tissue activity gradients. Model fits with three parameters K 1 (transport), k 2 (reverse transport) and k 3 (intracellular metabolism) were found to best illustrate [18F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [18F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [18F]FBPA influx constant (K i -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1–1.4. [18F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [18F]FBPA, some of these benign neoplasms may be amenable to BNCT.
- 1 November 2004
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 61 (5) , 975-979
Boron biodistribution in Beagles after intravenous infusion of 4-dihydroxyborylphenylalanine–fructose complex
- 1 November 2004
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 61 (5) , 975-979
Boron biodistribution in Beagles after intravenous infusion of 4-dihydroxyborylphenylalanine–fructose complex
- 1 July 2004
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 72 (1) , 83-85
Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy
- 1 July 2004
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 72 (1) , 83-85
Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy
- 1 April 2003
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 48 (8) , 1027-1039
1H MRS of a boron neutron capture therapy10B-carrier, L-p-boronophenylalanine fructose complex, BPA F: phantom studies at 1.5 and 3.0 T
The quantification of a BNCT 10B-carrier, L-p-boronophenylalanine-fructose complex (BPA-F), was evaluated using 1H magnetic resonance spectroscopy (1H MRS) with phantoms at 1.5 and 3.0 T. For proper quantification, relaxation times T1 and T2 are needed. While T1 is relatively easy to determine, the determination of T2 of a coupled spin system of aromatic protons of BPA is not straightforward with standard MRS sequences. In addition, an uncoupled concentration reference for aromatic protons of BPA must be used with caution. In order to determine T2, the response of an aromatic proton spin system to the MRS sequence PRESS with various echo times was calculated and the product of the response curve with exponential decay was fitted to the measured intensities. Furthermore, the response curve can be used to correct the intensities, when an uncoupled resonance is used as a concentration reference. BPA was quantified using both phantom replacement and internal water referencing methods with accuracies of +/- 5% and +/- 15%. Our phantom results suggest that in vivo studies on BPA concentration determination will be feasible.
- 1 April 2003
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 48 (8) , 1027-1039
1H MRS of a boron neutron capture therapy10B-carrier, L-p-boronophenylalanine fructose complex, BPA F: phantom studies at 1.5 and 3.0 T
The quantification of a BNCT 10B-carrier, L-p-boronophenylalanine-fructose complex (BPA-F), was evaluated using 1H magnetic resonance spectroscopy (1H MRS) with phantoms at 1.5 and 3.0 T. For proper quantification, relaxation times T1 and T2 are needed. While T1 is relatively easy to determine, the determination of T2 of a coupled spin system of aromatic protons of BPA is not straightforward with standard MRS sequences. In addition, an uncoupled concentration reference for aromatic protons of BPA must be used with caution. In order to determine T2, the response of an aromatic proton spin system to the MRS sequence PRESS with various echo times was calculated and the product of the response curve with exponential decay was fitted to the measured intensities. Furthermore, the response curve can be used to correct the intensities, when an uncoupled resonance is used as a concentration reference. BPA was quantified using both phantom replacement and internal water referencing methods with accuracies of +/- 5% and +/- 15%. Our phantom results suggest that in vivo studies on BPA concentration determination will be feasible.
- 1 March 2003
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 62 (1) , 123-134
Boron Neutron Capture Therapy of Brain Tumors: Clinical Trials at the Finnish Facility Using Boronophenylalanine
- 1 March 2003
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 62 (1) , 123-134
Boron Neutron Capture Therapy of Brain Tumors: Clinical Trials at the Finnish Facility Using Boronophenylalanine
- 1 February 2003
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 18 (2) , 155-163
Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway
- 1 February 2003
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 18 (2) , 155-163
Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway
- 1 January 1996
- Vol. 112 (11) , 970-4
[Boron neuron capture therapy in the treatment of brain tumors].
- 1 January 1996
- Vol. 112 (11) , 970-4
[Boron neuron capture therapy in the treatment of brain tumors].